logo
logo
IDEXX Laboratories, Inc.

IDEXX Laboratories, Inc.

NASDAQ•IDXX
CEO: Mr. Jonathan J. Mazelsky
セクター: Healthcare
業種: Medical - Diagnostics & Research
上場日: 1991-06-21
IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
連絡先情報
One IDEXX Drive, Westbrook, ME, 04092, United States
207-556-0300
www.idexx.com
時価総額
$49.28B
PER (TTM)
46.7
20
配当利回り
--
52週高値
$769.98
52週安値
$356.14
52週レンジ
63%
順位17Top 4.2%
6.4
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
強い • 6.4 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025

財務ダッシュボード

Q4 2025 データ

売上高

$1.09B+14.28%
直近4四半期の推移

EPS

$3.10+17.87%
直近4四半期の推移

フリーCF

$326.33M+46.49%
直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Total Revenue Growth Strong Total revenue reached $3.213 B USD for nine months, reporting 9.2% growth; organic revenue grew 8.7% compared to prior year.
Operating Income Surges Income from operations increased $177.775 M USD to $1.044 B USD, reflecting 20.5% growth for the nine months ended September 30.
Gross Margin Expansion Noted Total gross profit margin improved 90 basis points to 62.3% driven by recurring revenue volume and pricing benefits offsetting costs.
Operating Cash Flow Rises Cash provided by operating activities was $826.045 M USD, a $159.069 M USD increase year-to-date period compared to 2024.

リスク要因

Foreign Currency Headwinds Persist Strengthening U.S. dollar negatively impacts international revenue growth rates; projected to reduce revenue by $4 M USD remainder of 2025.
Litigation Settlement Paid Company paid $80 M USD judgment in April 2025 to conclude 2018 breach of contract royalty lawsuit; payment impacted cash flow.
Inflationary Cost Pressures Expect continued higher costs for labor, commodities, and transportation; may not fully offset these increases via productivity or pricing.
Tariff and Trade Uncertainty Changes in global tariff and trade policies create volatility and uncertainty, potentially reducing demand for products and services globally.

見通し

Strong Liquidity Position Net debt to Adjusted EBITDA ratio stands at 0.51, well below 3.5-to-1 covenant; $793.2 M USD availability remains under Credit Facility.
Tax Law Accelerates Deductions Acceleration of R&D deductions due to OBBBA expected to reduce projected 2025 income taxes due by approximately $105 M USD.
Debt Maturity Management Anticipate paying off $75.0 M USD 2025 Series B Notes in December 2025 using cash or Credit Facility borrowings as planned.
Capital Spending Planned Total capital expenditure plan for 2025 estimated at $140.0 M USD, focusing on manufacturing facilities and customer-facing software development.

同業比較

売上高 (TTM)

Cencora, Inc.COR
$325.78B
+7.4%
Cardinal Health, Inc.CAH
$244.49B
+10.1%
Takeda Pharmaceutical Company LimitedTAK
$30.01B
-2.0%

粗利益率 (最新四半期)

argenx SEARGX
88.3%
-53.8pp
Alnylam Pharmaceuticals, Inc.ALNY
84.2%
+1.4pp
Edwards Lifesciences CorporationEW
78.1%
-2.7pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
COR$68.29B42.0101.4%10.1%
BDX$64.41B28.86.4%32.8%
TAK$58.03B78.11.6%31.5%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
3.0%
緩やかな成長
4四半期純利益CAGR
0.8%
収益性の緩やかな改善
キャッシュフロー安定性
100%
優れたキャッシュフローの実績

深度リサーチ

次回決算:2026年4月29日
|
EPS:-
|
売上高:-
財務レポート
財務データ
全年度
  • Form 10-Q - Q3 2025

    会計期末: 2025年9月30日|提出日: 2025年11月3日|
    売上高: $1.11B+13.3%
    |
    EPS: $3.43+21.2%
    予想を上回る
  • Form 10-Q - Q2 2025

    会計期末: 2025年6月30日|提出日: 2025年8月4日|
    売上高: $1.11B+10.5%
    |
    EPS: $3.66+48.8%
    予想を上回る
  • Form 10-Q - Q1 2025

    会計期末: 2025年3月31日|提出日: 2025年5月1日|
    売上高: $998.43M+3.6%
    |
    EPS: $2.98+4.9%
    予想を上回る
  • Form 10-K - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年2月21日|
    売上高: $3.90B+6.5%
    |
    EPS: $10.77+5.9%
    予想通り
  • Form 10-Q - Q3 2024

    会計期末: 2024年9月30日|提出日: 2024年10月31日|
    売上高: $975.54M+6.6%
    |
    EPS: $2.83+11.0%
    予想を上回る
  • Form 10-Q - Q2 2024

    会計期末: 2024年6月30日|提出日: 2024年8月6日|
    売上高: $1.00B+6.4%
    |
    EPS: $2.46-8.9%
    予想を下回る
  • Form 10-Q - Q1 2024

    会計期末: 2024年3月31日|提出日: 2024年5月1日|
    売上高: $964.10M+7.1%
    |
    EPS: $2.84+10.1%
    予想を上回る
  • Form 10-K - FY 2023

    会計期末: 2023年12月31日|提出日: 2024年2月22日|
    売上高: $3.66B+8.7%
    |
    EPS: $10.17+25.2%
    予想を上回る